Literature DB >> 7741031

Gene transfer as cancer therapy.

G Dranoff1, R C Mulligan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7741031     DOI： 10.1016/s0065-2776(08)60624-0

Source DB:  PubMed          Journal:  Adv Immunol        ISSN： 0065-2776            Impact factor:   3.543


× No keyword cloud information.
  15 in total

1.  Will modern cancer vaccines reach clinical practice?

Authors:  G Masucci
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

Review 2.  Recent advances: oncology.

Authors:  M H Tattersall; H Thomas
Journal:  BMJ       Date:  1999-02-13

3.  Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.

Authors:  J C Becker; N Varki; S D Gillies; K Furukawa; R A Reisfeld
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

4.  Antitumor immunity induced by irradiated tumor cells producing macrophage colony-stimulating factor.

Authors:  S Suzu; F Kimura; M Tanaka-Douzono; M Yamada; Y Nakamura; N Wakimoto; K Sato; T Morita; K Ikeda; K Motoyoshi
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

5.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Authors:  J L Schultze; A A Cardoso; G J Freeman; M J Seamon; J Daley; G S Pinkus; J G Gribben; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

6.  p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

Authors:  J Roth; D Dittmer; D Rea; J Tartaglia; E Paoletti; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

7.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

Authors:  L W Kwak; H A Young; R W Pennington; S D Weeks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

8.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

Authors:  R Soiffer; T Lynch; M Mihm; K Jung; C Rhuda; J C Schmollinger; F S Hodi; L Liebster; P Lam; S Mentzer; S Singer; K K Tanabe; A B Cosimi; R Duda; A Sober; A Bhan; J Daley; D Neuberg; G Parry; J Rokovich; L Richards; J Drayer; A Berns; S Clift; L K Cohen; R C Mulligan; G Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

9.  Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries.

Authors:  X Cai; A Garen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

10.  Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations.

Authors:  T Schweighoffer
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 2.874
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.